SCHEMBL11992017

SCHEMBL11992017

Nc1ncc(-c2cccc(-c3ccco3)c2)nc1C(=O)c1cccnc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 1/20 0.56
CDK5R1 Q15078 1/20 0.56
PIK3CD O00329 1/20 0.51
ATR Q13535 13/20 0.50
CYP3A4 P08684 1/20 0.46
KEAP1 Q14145 1/20 0.45
MAPT P10636 2/20 0.45
HSD17B10 Q99714 2/20 0.45
F2 P00734 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
BRCA1 P38398 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407317 0.84 CDK5 (0.63) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3402771 0.84 CDK5 (0.66) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3408468 0.83 CDK5 (0.62) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3405958 0.82 CDK5 (0.61) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3411290 0.80 CDK5 (0.59) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3405191 0.80 CDK5 (0.61) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3430137 0.78 ATR (0.61) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3408472 0.78 CDK5 (0.57) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL27837070 0.78 CDK5 (0.56) CDK5CDK5R1PIK3CDATRCYP3A4
SCHEMBL3411415 0.78 PIK3CD (0.68) CDK5CDK5R1PIK3CDATRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846687-B2 Pyrazine compounds as PI3 kinase inhibitors NOVARTIS AG (CH) 2014-09-30 US disclosed
US-8846687-B2 Pyrazine compounds as PI3 kinase inhibitors NOVARTIS AG (CH) 2014-09-30 US disclosed
EP-2597085-A1 Organic compounds Novartis AG (CH) 2013-05-29 EP disclosed
US-8268834-B2 Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme NOVARTIS AG (CH) 2012-09-18 US disclosed
US-8268834-B2 Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme NOVARTIS AG (CH) 2012-09-18 US disclosed
US-20120214800-A1 Organic Compounds NOVARTIS AG (CH) 2012-08-23 US disclosed
US-20120214800-A1 Organic Compounds NOVARTIS AG (CH) 2012-08-23 US disclosed
WO-2009115517-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-24 WO disclosed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 US disclosed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239847-A1 Organic compounds AR, TRPA1, IL33 CDK5 4241/4885CDK5R1 3299/4885PIK3CD 4406/4885
US-20120214800-A1 Organic Compounds AR, TRPA1, IL33 CDK5 4241/4885CDK5R1 3299/4885PIK3CD 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.